UK scientists developing Ebola vaccine that could be ready for trials in months

The rare species of Ebola involved - known as Bundibugyo - kills around a third of those infected and has no proven vaccine yet.

Oxford Vaccine Group is collaborating with the Serum Institute of India to rapidly produce doses of the ChAdOx1 BDBV vaccine, aiming for clinical trials in outbreak scenarios while adhering to scientific, ethical, and regulatory standards.

Oxford University scientists are developing a new Ebola vaccine using the same technology as the COVID-19 jab to address the Bundibugyo strain outbreak in the Democratic Republic of the Congo, which has resulted in 177 deaths.

Scientists at Oxford University are developing a vaccine for the rare Bundibugyo species of Ebola, with the World Health Organization upgrading the risk level in the Democratic Republic of Congo to 'very high' as suspected cases reach 750 with 177 deaths.

Oxford University scientists are urgently developing a vaccine for the Bundibugyo strain of Ebola, with animal testing underway and the World Health Organization indicating it could be ready for clinical trials within two to three months.

Researchers at Oxford University are developing a vaccine targeting the rare Bundibugyo strain of Ebola, with clinical trials potentially starting in two to three months if animal tests are successful.